Brain Trauma Blueprint - 2019 State of the Science Summit Agenda

2019 State of the Science Summit
Paths to Treatment for Traumatic Brain Injury(s)

June 5-6, 2019 – Washington, D.C.

Agenda

Day 1: June 5, 2019

Time	Session	Details/Goal	Presenter
7:30 – 8:30 am	Arrivals, Registration, & Breakfast
8:30 am	Announcements	Event Mobi App Tutorial Pre-read homework survey – Interactive Session
8:45 am	Patient Perspectives on Chronic Sequalae of TBI
9:00 am	Welcome by Cohen Veterans Bioscience	Announcements, Blueprint Overview and SoSS2 Goals	Magali Haas, MD, PhD CEO & President, Cohen Veterans Bioscience Nicole Harmon, PhD Executive Director, Community Partnerships, Cohen Veterans Bioscience
9:30 am	Keynote: Call to Action for TBI	Focus on classification, biomarkers, and challenges for treatment	David Brody, MD, PhD Director at Center for Neuroscience and Regenerative Medicine, The USU/NIH Traumatic Brain Injury Research Group
10:00 am	Implementation Science: The Clinical Perspective	Current practice model Acute Care Radiologic Diagnosis Rehabilitation Medicine Practice Guidelines	Moderator: Noel Gunther Executive Director, BrainLine Uzma Samadani, MD, PhD Associate Professor, Department of Neurosurgery, Medical School, Neurosurgeon, Minneapolis VA Medical Center, Rockswold Kaplan Endowed Chair for Traumatic Brain Injury Research, HCMC Christopher T. Whitlow, MD, PhD, MHA Chair of American College of Radiology Head Injury Institute, Diagnostic Radiologist Researcher at Wake Forest Baptist Health Hospital David Cifu, MD Senior TBI Specialist, U.S. Department of Veterans Affairs Thomas DeGraba, MD Chief Innovations Officer, National Intrepid Center of Excellence
10:45 am	Break
11:00 am	National Priorities: Government Investment	Portfolio investments to date and priorities by institution	Stuart Hoffman, PhD Scientific Program Manager for Brain Health & Injury at U.S. Department of Veterans Affairs Patrick Bellgowan, PhD Program Director, Repair & Plasticity, National Institute for Neurological Diseases & Stroke Carlos Peña, PhD Director, Office of Neurological and Physical Medicine Devices (OHT5), Office of Product Evaluation and Quality (OPEQ) ,Center for Devices and Radiological Health, FDA Saafan Malik, MD Director of Research & Acting Deputy Division Chief, Defense & Veterans Brain Injury Center J9- Research & Development Directorate, Defense Health Agency
12:00 pm	Lunch
1:00 pm	Introduction of Scientific Planning Committee & Breakout Overview Goals		Retsina Meyer, PhD Senior Manager, Clinical Programs, Cohen Veterans Bioscience
1:10 pm	Current State of the Science: multidisciplinary assessment		Fiona Crawford, PhD President & CEO, Roskamp Institute Jam Ghajar, MD, PhD, FACS President, Brain Trauma Foundation, Clinical Professor of Neurosurgery at Stanford University School of Medicine Jessica Gill, PhD, RN, FAAN Deputy Scientific Director of the Division of Intramural Research at the National Institute of Nursing Research Grant Iverson, PhD Director, Neuropsychology Outcome Assessment Laboratory, Department of Physical Medicine and Rehabilitation, Harvard Medical School, and Spaulding Rehabilitation Network
2:15 pm	Break & move to breakouts
2:30 pm	Domain Breakouts	Review of synthesis/identification of gaps and new directions PreClinical/Translational: Scientific Planning Committee Leads: Fiona Crawford, PhD Roskamp Institute Stephen Ahlers, PhD Naval Medical Research Center Extended Scientific Planning Committee Members: Patrick Kochanek, MD, MCCM University of Pittsburgh Mary Jo Pugh, PhD, RN, FAAN University of Utah Susanna Rosi, PhD UCSF Doug Smith, MD University of Pennsylvania Phenotypes/Biotypes: Scientific Planning Committee Lead: Jam Ghajar, MD, PhD, FACS Brain Trauma Foundation/Stanford University Extended Scientific Planning Committee Members: Adam Ferguson, PhD UCSF Anthony Kontos, PhD University of Pittsburgh Biomarker Development: Scientific Planning Committee Leads: Jessica Gill, PhD, RN, FAAN NINR James Stone, MD, PhD University of Virginia Lisa Wilde, PhD Baylor University Extended Scientific Planning Committee Members: Kimbra Kenney, MD USUHS/ NICoE, WRNMMC Ina Wanner, PhD UCLA Clinical Trial Design: Scientific Planning Committee Leads: Grant Iverson, PhD Harvard/Spaulding Rehabilitation Network David Cifu, MD Virginia Commonwealth University/VA Extended Scientific Planning Committee Members: Mike Bell, MD Children’s National Health System Lisa Brenner, PhD, ABPP VA Rocky Mountain Mental Illness Research Education and Clinical Center David Brody, MD, PhD USU/NIH Don Stein, PhD Emory University School of Medicine David Wright, MD, FACEP Emory University School of Medicine	Breakout Moderators: Preclinical/Translational: Chantelle Ferland-Beckham, PhD Senior Manager, Scientific Programs, Cohen Veterans Bioscience Phenotypes/Biotypes: Lee Lancashire, PhD Chief Information Officer, Cohen Veterans Bioscience Biomarker Development: Rajeev Ramchand, PhD Senior Vice President, Research, Cohen Veterans Network Clinical Trial Design: David Biondi, DO, FAAN Executive Director, Clinical Programs, Cohen Veterans Bioscience
5:30 pm	Wrap Up Day 1	Summarize Day 1 Highlights and Discuss Day 2 Goals	Dallas Hack, MD Colonel, U.S. Army (Retired), Veterans Science Strategy Advisor, Cohen Veterans Bioscience
6:00 pm	Adjourn
6:00 pm	Appetizers & Cocktails
7:30 pm	Dinner

Day 2: June 6, 2019

Time	Session	Details/Goal	Presenter
7:30 – 8:00 am	Arrivals & Breakfast
8:15 am	TBI Policy Update		Roger Murry Executive Director, Coalition to Heal Invisible Wounds
8:30 am	Review of Day 1 Discussion	Interactive Survey Questions from Day 1 Discussion/Comments & Goals for Day 2	Panel of Domain Leaders: Lisa Brenner, PhD, ABPP VA Rocky Mountain Mental Illness Research Education and Clinical Center Anthony Kontos, PhD Assistant Director of Research, University of Pittsburgh Medical Center Doug Smith, MD Robert A. Groff Professor Of Teaching And Research In Neurosurgery, Perelman School of Medicine, University of Pennsylvania Elisabeth Wilde, PhD Associate Professor, Director of Research for Physical Medicine and Rehabilitation, Baylor College of Medicine
9:30 am	Advancing Brain Health for TBI: Quantitative Neuroimaging for Precision Medicine and Clinical Translation in the Learning Healthcare System		Christopher T. Whitlow, MD, PhD, MHA Chair of American College of Radiology Head Injury Institute, Diagnostic Radiologist Researcher at Wake Forest Baptist Health Hospital
10:00 am	R&D and Regulatory Challenges Panel	Real world experience on approval process, including hurdles each company faced. How could this blueprint have been useful/improved the process?	Moderator: Magali Haas, MD, PhD CEO & President, Cohen Veterans Bioscience Ronald L. Hayes, PhD Founder and Chief Science Officer, Banyan Biomarkers, Inc. Stephen Xenakis, MD Brigadier General (Ret.), U.S. Army, Fisher Wallace Laboratories William S. Korinek, PhD CEO, Astrocyte Pharmaceuticals, Inc. Rosina Samadani, PhD CEO, Oculogica Michael E. Singer, PhD CEO, BrainScope Company, Inc. Michael Hoffman Deputy Director, Division of Neurological and Physical Medicine Devices, FDA
11:00 am	Working Group Lunch with Multi-disciplinary Breakouts	Identify & prioritize opportunities to address key gaps & new directions PreClinical/Translational: Scientific Planning Committee Leads: Fiona Crawford, PhD Roskamp Institute Stephen Ahlers, PhD Naval Medical Research Center Extended Scientific Planning Committee Members: Patrick Kochanek, MD, MCCM University of Pittsburgh Mary Jo Pugh, PhD, RN, FAAN University of Utah Susanna Rosi, PhD UCSF Doug Smith, MD University of Pennsylvania Phenotypes/Biotypes: Scientific Planning Committee Lead: Jam Ghajar, MD, PhD, FACS Brain Trauma Foundation/Stanford University Extended Scientific Planning Committee Members: Adam Ferguson, PhD UCSF Anthony Kontos, PhD University of Pittsburgh Biomarker Development: Scientific Planning Committee Leads: Jessica Gill, PhD, RN, FAAN NINR James Stone, MD, PhD University of Virginia Lisa Wilde, PhD Baylor University Extended Scientific Planning Committee Members: Kimbra Kenney, MD USUHS/ NICoE, WRNMMC Ina Wanner, PhD UCLA Clinical Trial Design: Scientific Planning Committee Leads: Grant Iverson, PhD Harvard/Spaulding Rehabilitation Network David Cifu, MD Virginia Commonwealth University/VA Extended Scientific Planning Committee Members: Mike Bell, MD Children’s National Health System Lisa Brenner, PhD, ABPP VA Rocky Mountain Mental Illness Research Education and Clinical Center David Brody, MD, PhD USU/NIH Don Stein, PhD Emory University School of Medicine David Wright, MD, FACEP Emory University School of Medicine	Breakout Moderators: PreClinical/Translational: Chantelle Ferland-Beckham, PhD Senior Manager, Scientific Programs, Cohen Veterans Bioscience Phenotypes/Biotypes: Lee Lancashire, PhD Chief Information Officer, Cohen Veterans Bioscience Biomarker Development: Rajeev Ramchand, PhD Senior Vice President, Research, Cohen Veterans Network Clinical Trial Design: David Biondi, DO, FAAN Executive Director, Clinical Programs, Cohen Veterans Bioscience
1:30 pm	Closing Session	Working Group Development & Summary of Summit	Rachel Ramoni, DMD, ScD Chief Research and Development Officer, U.S. Department of Veterans Affairs
2:00 pm	Adjourn		Nicole Harmon, PhD Executive Director, Community Partnerships, Cohen Veterans Bioscience